| Previous Close | 73.12 |
| Open | 73.19 |
| Bid | 71.51 x 100 |
| Ask | 73.35 x 200 |
| Day's Range | 73.12 - 73.77 |
| 52 Week Range | 63.76 - 82.10 |
| Volume | 5,237,298 |
| Avg. Volume | 8,734,245 |
| Market Cap | 95.8B |
| Beta | 1.08 |
| PE Ratio (TTM) | 7.75 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 2.08 (2.87%) |
| Ex-Dividend Date | 2017-09-14 |
| 1y Target Est | N/A |
Zacks•12 hours agoFalling Earnings Estimates Signal Weakness Ahead for Mylan (MYL)
Mylan (MYL) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Zacks•13 hours agoBiotech Stock Roundup: Regeneron Drops RSV Antibody, Gilead HIV Drug Gets Priority Review
This week, companies like Regeneron (REGN) and Ionis provided updates on their pipeline while Gilead announced priority review for its HIV drug.
- Motley Fool•yesterday
Why Gilead Sciences Might Not Make an Oncology Acquisition
Gilead Sciences' CEO hints that buying a biotech with an oncology focus might not happen. Here's what this could mean for the big biotech.
